Business Update Positive

2026-05-21 12:23

Solara Active Pharma Sciences reported a strong Q4 FY26, achieving its highest revenue (INR 392 Cr, ▲12% QoQ), gross margins (47%), and EBITDA (INR 61 Cr, ▲65% QoQ) in 8 quarters, driven by its profitable base business (26% EBITDA margin). The company is evaluating strategic options for its loss-making Ibuprofen business and the mothballed Vizag facility. Debt was reduced by INR 158 Cr in FY26, targeting debt-free status by FY29. Management plans 4-5 new DMF filings annually, focusing on operational efficiency and existing capacity for future growth.

Business Update Neutral

2026-05-15 17:31

Solara Active Pharma Sciences Limited announced the upload of the audio recording of its Q4 FY26 earnings call, conducted on May 15, 2026. The call discussed the financial results for the quarter and year ended March 31, 2026. The recording is available on the company's website under the Investor Relations section.

Governance Neutral

2026-05-15 14:49

On May 15, 2026, Solara Active Pharma Sciences Limited's Board of Directors adopted a 'Board Evaluation Policy' and amended its 'Whistle Blower Policy' to comply with SEBI Listing Regulations. The revised policies are available on the company's website.

Ownership Neutral

2026-05-15 14:41

Solara Active Pharma Sciences Limited's Board of Directors approved the allotment of 2,200 fully paid-up Equity Shares with a face value of Rs. 10/- each on May 15, 2026. This allotment is pursuant to the exercise of vested options under the Solara Employee Stock Option Plan 2018, which will increase the company's paid-up share capital.

Governance Neutral

2026-05-15 14:29

Solara Active Pharma Sciences Limited re-appointed M/s. Grant Thornton Bharat LLP as Internal Auditors and Mr. M K. Suryanarayanan as Cost Auditors for the financial year 2026-27. These re-appointments were approved by the Board of Directors at their meeting held on May 15, 2026.

Ownership Neutral

2026-05-15 14:12

Solara Active Pharma Sciences announced the receipt of ₹129.94 Crores as Second & Final call money for 1,15,50,478 Rights Equity Shares. The Board, in its meeting on May 15, 2026, approved the conversion of these partly paid-up equity shares (ISIN IN9624Z01022) into fully paid-up equity shares (ISIN INE624Z01016) at Rs. 112.50/- per share. The company will take necessary steps for listing and trading approvals.

Financials Positive

2026-05-15 13:23

Solara Active Pharma Sciences reported Consolidated Revenue of ₹3,919Cr for Q4'26, reflecting a ▲40% YoY growth compared to ₹2,799Cr in Q4'25. Consolidated EBITDA stood at ₹617Cr for Q4'26, noted as the highest in eight quarters. PAT was not disclosed. The Base business showed strong momentum with revenue growth of 36% YoY and EBITDA growth of 16% YoY, while the Ibuprofen business faced significant headwinds with revenue declining 61% YoY and negative EBITDA.

Financials Positive

2026-05-15 13:18

Solara Active Pharma Sciences Limited reported strong Q4 FY26 consolidated results. Consolidated Revenue was ₹387.29 Cr compared to ₹273.01 Cr in Q4 FY25, marking a 41.86% Year-on-Year increase. EBITDA stood at ₹58.52 Cr against ₹45.37 Cr in Q4 FY25, a 29.00% YoY rise. The company turned profitable with PAT of ₹9.60 Cr compared to a loss of ₹(2.10) Cr in the corresponding previous quarter. However, the EBITDA Margin contracted to 15.11% from 16.62% (▼151bps).

Business Update Neutral

2026-05-12 20:17

Solara Active Pharma Sciences Limited announced a revised intimation for its Analysts/Investors Conference Call scheduled for Friday, May 15, 2026, at 3:00 PM IST. The call is to discuss the audited financial results for the quarter and year ended March 31, 2026. One panel member is unable to attend due to a scheduling conflict, but the remaining panel will participate as planned, and all other details remain unchanged.

Business Update Neutral

2026-05-11 16:35

Solara Active Pharma Sciences Limited announced an Analysts/Investors Conference Call to discuss its audited financial results for the quarter and financial year ended March 31, 2026. The conference call is scheduled for Friday, May 15, 2026, at 3:00 P.M (IST).

Business Update Positive

2026-04-28 17:03

Solara Active Pharma Sciences announced the successful closure of its US FDA inspection for the Puducherry facility. The inspection, conducted Feb 2-6, 2026, resulted in a 'Voluntary Action Indicated (VAI)' classification and was concluded as 'Closed' on April 24, 2026.

Ownership Neutral

2026-04-07 19:46

Solara Active Pharma Sciences Limited issued the Second and Final Call Notice for ₹112.50 per partly paid Rights equity share. Payment is due between April 23 and May 07, 2026, to fully convert the shares. This finalizes the rights issue payment. Trading of the partly paid shares has been suspended procedurally.

Routine Neutral

2026-03-30 20:08

New Filing detected. See link for details.

Routine Neutral

2026-03-26 16:08

Solara Active Pharma Sciences Limited announced the closure of its trading window from April 1, 2026, until 48 hours after the declaration of financial results for the quarter and year ended March 31, 2026, in compliance with SEBI PIT Regulations.

Business Update Neutral

2026-03-24 10:39

The Rights Issue Committee approved the Second & Final call of ₹112.50 per partly-paid Rights Share (₹3.00 face value + ₹109.50 securities premium). The record date for determining eligible holders is April 02, 2026, for payment dispatch.

Business Update Neutral

2026-03-24 10:26

Solara Active Pharma Sciences Limited's Rights Issue Committee approved the Second & Final call of ₹ 112.50/- per equity share for partly-paid Rights Shares. Thursday, April 02, 2026, has been fixed as the Record Date for determining eligible holders for the call notice dispatch.

Governance Positive

2026-03-24 10:20

Solara Active Pharma Sciences announced the outcome of its Rights Issue Committee meeting, approving the Second & Final call of ₹112.50 per equity share on partly-paid Rights Shares. The record date for determining eligible holders is April 02, 2026.

Business Update Negative

2026-03-18 19:04

CRITICAL RED FLAG DETECTED

Solara Active Pharma Sciences received a tax demand notice for ₹161.92 Crores from the Income Tax Department for AY 2019-20 due to disallowance of certain expenses. The company plans to appeal the order, stating it does not expect a material financial impact.

Governance Positive

2026-03-10 13:02

Shareholders of Solara Active Pharma Sciences Limited approved the appointment of Mr. Mohanraj Sanjeevi (DIN: 08420411) as a Whole-time Director (Executive Director) via postal ballot. The resolution passed with an overwhelming majority of 99.97% votes in favour. The appointment is for a period of three years, effective January 01, 2026.

Ownership Positive

2026-03-04 18:52

Solara Active Pharma Sciences announced receipt of ₹93,71,512.50 for 71,402 partly paid-up Rights Equity Shares from the first call. These shares are converted from ₹3.50 to ₹7 paid-up. The company's total paid-up capital increased to ₹44,51,39,030.50, and steps will be taken for listing and trading approvals.

Business Update Neutral

2026-03-04 17:03

Solara Active Pharma Sciences Limited announced the voluntary deregistration of its wholly-owned non-operating subsidiary, Solara Active Pharma Sciences LTDA, Brazil, with effect from July 30, 2025. The subsidiary had nil turnover and net worth for FY25 and no business activities.

Business Update Negative

2026-02-10 17:53

Solara's Q3 FY26 earnings concall revealed ongoing struggles in its ibuprofen business due to headwinds, low capacity utilization, and 'depressing' consolidated results. While non-ibuprofen segments perform well, gross margins were hit. Debt was reduced by INR146 crores, and the Vizag plant remains mothballed as the company seeks ibuprofen strategy advice.

Business Update Neutral

2026-02-06 18:52

Solara Active Pharma Sciences Limited announced the uploading of the audio recording of its Q3 FY26 earnings call, held on February 06, 2026, for the quarter ended December 31, 2025, on the company's website.

Routine Neutral

2026-02-06 18:35

Solara Active Pharma Sciences Limited filed its Monitoring Agency Report for the quarter ended December 31, 2025, confirming no deviation in the utilization of Rights Issue proceeds. CRISIL Ratings stated that no proceeds were utilized during the reported quarter.

Business Update Neutral

2026-02-06 14:39

Solara Active Pharma Sciences Limited confirmed no deviation or variation in the utilization of ₹308.85 Cr raised through its Rights Issue for the quarter ended December 31, 2025. The Audit Committee reviewed and approved the statement for submission to the stock exchanges.

Governance Neutral

2026-02-06 14:20

On February 06, 2026, the Board approved amendments to the 'Policy for Determining Materiality of Events / Information for Disclosure to Stock Exchanges' and adopted a revised 'Policy for Governance of Related Party Transactions' to align with SEBI Regulations.

Financials Positive

2026-02-06 14:11

Solara's Q3'26 performance was driven by high-growth APIs (Revenue ₹2,466Cr, EBITDA ₹608Cr, EBITDA Margin 24.7%). The Ibuprofen API segment remains a drag (EBITDA -₹234Cr, EBITDA Margin -22.9%). The Board is evaluating options for the Ibuprofen business and re-assessing the CRAMS & Polymers business split.

Financials Negative

2026-02-06 13:48

CRITICAL RED FLAG DETECTED

Consolidated Revenue ₹349.00 Cr vs ₹300.31 Cr (▲16.21% YoY), EBITDA ₹30.59 Cr vs ₹57.68 Cr (▼46.96% YoY), PAT (Loss) ₹17.43 Cr vs Profit ₹8.09 Cr (▼315.45% YoY). EBITDA Margin 8.76% vs 19.21% (▼1045bps). The company reported accumulated losses and net current liabilities exceeding net current assets, necessitating a 'going concern' basis for financial reporting.

Routine Neutral

2026-02-05 23:35

Solara Active Pharma Sciences Limited informed about the publication of newspaper advertisements on February 05, 2026, regarding the dispatch of a Postal Ballot Notice dated February 04, 2026, to its members, as per Regulation 30 of SEBI Listing Regulations.

Financials Neutral

2026-02-03 15:05

Solara Active Pharma Sciences revised the time for its Q3FY26 earnings conference call to discuss unaudited financial results for the quarter ended December 31, 2025. The call, scheduled for February 06, 2026, will now be held at 3:30 PM IST instead of the previously intimated 4:30 PM IST.

Business Update Neutral

2026-01-30 21:06

Solara Active Pharma Sciences announced an analysts/investors conference call on February 6, 2026, at 4:30 PM IST, to discuss its unaudited financial results for the quarter and nine months ended December 31, 2025.

SOLARA

Solara Active Pharma Sciences Limited

Filing History

Unlock Full History